Finland-based biopharmaceutical firm Faron Pharmaceuticals has received recommendation from the Independent Data Monitoring Committee (IDMC) to continue its Phase III clinical trial (INTEREST) of Traumakine (FP-1201-lyo) to treat moderate-to-severe acute respiratory distress syndrome (ARDS).

Based on recombinant human intra-venous interferon beta (IFN beta-1a), Traumakine is being developed to prevent vascular beds leakage in acute lung injuries.

The double-blind, randomised, parallel-group Phase III INTEREST trial will evaluate the efficacy and safety of Traumakine compared to placebo.

Being performed at 60 hospital intensive care units (ICU) in Belgium, Finland, France, Germany, Italy, Spain and the UK, the trial is expected to conclude enrolment of 300 subjects in the fourth quarter of this year.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

See Also:

"The aim of this programme is to provide continued access to Traumakine once the INTEREST trial sites close, until conclusion of the regulatory approval process."

The primary efficacy endpoint of the trial is all-cause mortality rate at day 28, with a trial protocol target of 50% decrease in all cause mortality at day 28 between placebo and treatment arm.

Following the completion of patient recruitment, the firm intends to initiate an expanded access programme to allow use of Traumakine for eligible patients at ICU hospitals in Europe before the regulatory approval.

Faron Pharmaceuticals CEO Dr Markku Jalkanen said: “Given this imminent completion, and based on the potential benefits that Traumakine could offer, further supported by another successful safety review, we plan to set up a compassionate use programme for named patients with this severe disease following closure of the trial.

“The aim of this programme is to provide continued access to Traumakine once the INTEREST trial sites close, until conclusion of the regulatory approval process.”

Image: Chest X-ray of a patient with ARDS. Photo: courtesy of Samir/Wikipedia.